Evidence of FOXA1 involvement in tumor progression on the (epi)genetic, transcriptomic, and proteomic levels warrants further investigation of FOXA1 as clinical biomarker and its clinical utility for DCIS risk stratification. The gene discussed is FOXA1; the disease is neoplasm.